Scarica l'app Stockscreener
35.20
2.95%
1.01
Dopo l'orario di chiusura:
35.20
Precedente Chiudi:
$34.19
Aprire:
$33.97
Volume 24 ore:
1.43M
Relative Volume:
1.56
Capitalizzazione di mercato:
$2.06B
Reddito:
$54.03M
Utile/perdita netta:
$-412.78M
Rapporto P/E:
-4.9446
EPS:
-7.1189
Flusso di cassa netto:
$-377.29M
1 W Prestazione:
+17.53%
1M Prestazione:
+20.55%
6M Prestazione:
-11.85%
1 anno Prestazione:
+23.77%
Intervallo 1D:
$33.52
$35.34
Intervallo di 1 settimana:
$29.03
$36.35
Portata 52W:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Nome
Agios Pharmaceuticals Inc
Settore
Industria
Telefono
617-649-8600
Indirizzo
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
35.20 | 2.06B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-11-20 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Iniziato | H.C. Wainwright | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-09-27 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Iniziato | Piper Sandler | Overweight |
| 2022-11-17 | Aggiornamento | Goldman | Sell → Neutral |
| 2022-07-27 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Iniziato | BofA Securities | Buy |
| 2021-07-30 | Downgrade | Goldman | Neutral → Sell |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-02-15 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Iniziato | Leerink Partners | Mkt Perform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-04-11 | Reiterato | Credit Suisse | Outperform |
| 2018-02-15 | Reiterato | Needham | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-08-10 | Reiterato | Needham | Buy |
| 2017-08-08 | Reiterato | SunTrust | Buy |
| 2017-08-02 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Downgrade | Janney | Buy → Neutral |
| 2017-01-17 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Iniziato | Needham | Buy |
| 2016-06-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Reiterato | SunTrust | Buy |
Mostra tutto
Agios Pharmaceuticals Inc Borsa (AGIO) Ultime notizie
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - Sahm
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
AGIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance Australia
Agios to seek accelerated approval in US of oral mitapivat for SCD - Sickle Cell Disease News
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
Insider sale and RSU vesting at AGIO (Nasdaq: AGIO) — 2,959 shares - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
3,280 RSUs vest; James Burns sold 5,218 shares — AGIO (NASDAQ: AGIO) - Stock Titan
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD - Bitget
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - finance.yahoo.com
Earnings Recap: Is Agios Pharmaceuticals Inc a good ESG investment2026 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Agios to pursue accelerated approval for mitapivat in sickle cell By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $65 - Moomoo
The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios (AGIO) Files for Accelerated Approval of Mitapivat in Sick - GuruFocus
Agios Shares Rise After Plans for Accelerated Approval Filing of Mitapivat in Sickle Cell Disease - MarketScreener
BofA raises Agios Pharma stock price target on SCD filing path By Investing.com - za.investing.com
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? - Benzinga
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - The Motley Fool
BofA raises Agios Pharma stock price target on SCD filing path - au.investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap UpHere's Why - MarketBeat
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga
Truist reiterates Agios Pharma stock rating on accelerated approval path - Investing.com
Agios (AGIO) Sees 13% Boost Following Approval Pursuit for Mitap - GuruFocus
Agios Pharmaceuticals (AGIO) Seeks Accelerated FDA Approval for Sickle Cell Treatment - GuruFocus
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - seekingalpha.com
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - Morningstar
Agios stock surges on FDA path for mitapivat approval By Investing.com - Investing.com Canada
Agios to pursue accelerated approval for mitapivat in sickle cell - Investing.com
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA - The Manila Times
Agios moves oral sickle cell drug toward faster U.S. approval - Stock Titan
Agios Pharmaceuticals Receives 'Hold' Rating from Analysts - National Today
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A. - MarketBeat
Why Agios Pharmaceuticals (AGIO) Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Pass Below 200-Day Moving AverageHere's Why - MarketBeat
Agios Pharmaceuticals leukemia drug gets U.S. approval - AOL.com
(AGIO) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Agios Pharmaceuticals stock declines 23% in 6 months: Here's why - MSN
Vanguard (NYSE: V) disaggregates Agios holdings; reports 0% ownership - Stock Titan
AGIO STOCK ALERT: Levi & Korsinsky Notifies Agios Pharmaceuticals, Inc. Investors of an Ongoing Investigation - GuruFocus
Agios Pharmaceuticals Inc Azioni (AGIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):